NOV:ETR
Novo Nordisk A/S
€37.14
arrow_upward
+0.92%(+0.34) 1D
Nov 13, 5:35:34 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NOV...
Open
€36.82
High
€37.22
Low
€36.68
Mkt. cap
142.04B
Avg. vol.
143.27K
Volume
131.99K
52-wk high
€54.87
52-wk low
€30.24
No. of employees
67K
Open
€36.82
High
€37.22
Low
€36.68
Mkt. cap
142.04B
Avg. vol.
143.27K
Volume
131.99K
52-wk high
€54.87
52-wk low
€30.24
No. of employees
67K
News stories
From web sources and news partners
The Motley Fool
·
5 hours ago
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?
Traders Union
·
1 day ago
Novo Nordisk stock rises over 2% as company pledges $200 million to World Diabetes Foundation and lifts guidance
The Motley Fool
·
2 days ago
JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?
TradingView
·
3 days ago
Will Wegovy Pill Drive Renewed GLP-1 Growth Momentum for Novo Stock?
Profile
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 69,500 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
About Novo Nordisk A/S
CEOMike Doustdar
Employees66.7K
Founded1923
HeadquartersBagsværd, Capital Region of Denmark, Denmark
SectorHealth Care
IndustryPharmaceutical industry
Websitenovonordisk.com